Mexedrone

# Research Output: Mexedrone

## Chemical Identity

**Confirmed via PubChem CID 129318262** [Ref 1 — database lookup]:

- **Molecular formula:** C₁₂H₁₇NO₂
- **Molecular weight:** 207.27 g/mol
- **IUPAC name:** 3-methoxy-2-(methylamino)-1-(4-methylphenyl)propan-1-one
- **InChIKey:** JHGDCSPZKQLBOP-UHFFFAOYSA-N
- **PubChem CID:** 129318262
- **Systematic name:** Consistent with brief seed data
- **SMILES:** Not returned by PubChem API; see brief note in Gaps & Flags
- **CAS number:** Not retrieved via API

**Physical form:** White to colorless crystalline powder (Reagent Tests UK observation [Ref 20])

**Crystal structure:** Full X-ray crystal structure analysis obtained and reported by McLaughlin et al. (2017 [Ref 1]), enabling definitive structural confirmation and differentiation from the positional isomer N-methoxymephedrone.

**Structural relationship:** Mexedrone is the alpha-methoxy derivative of mephedrone (4-methylmethcathinone, 4-MMC). The methoxy group is introduced at the alpha position (beta-keto side chain), rendering it structurally distinct from the beta-methoxy position of mephedrone and from N-methoxymephedrone (its N-methoxy positional isomer). McLaughlin et al. (2017 [Ref 1]) confirmed that the alpha-chloromethylmephedrone is produced as a synthesis by-product.

**Stereochemistry:** Mexedrone possesses a chiral center at C-2 (the alpha-carbon). Published data do not specify the racemic versus enantiopure form sold on the research chemical market, and no published enantiomer-specific pharmacology has been identified. The InChIKey (JHGDCSPZKQLBOP-UHFFFAOYSA-N) is the standard (non-stereochemical) form, confirming it is typically characterized as the racemate.

**Seed data discrepancies:** PubChem CID, molecular formula, molecular weight, and InChIKey were all absent from the seed data and are now confirmed. These should be populated in the database.

---

## Pharmacology

### Monoamine Transporter Activity

The primary pharmacological characterization of mexedrone was published by McLaughlin et al. (2017 [Ref 1]) using in vitro monoamine transporter assays in rat brain synaptosomes. Key findings:

- **DAT (Dopamine Transporter):** Mexedrone is a weak uptake blocker (inhibitor) with IC₅₀ in the low micromolar range. It is **devoid of releasing activity at DAT**. This makes it a reuptake inhibitor, not a dopamine releaser.
- **NET (Norepinephrine Transporter):** Weak non-selective uptake blocker at low μM IC₅₀. **Devoid of releasing activity at NET**. Not a norepinephrine releaser.
- **SERT (Serotonin Transporter):** Weak uptake blocker at low μM IC₅₀. **Weak releasing activity at SERT** (EC₅₀ = 2.5 μM) — the only transporter at which mexedrone acts as a substrate-type releaser.

**Overall mechanism:** Mexedrone is best classified as a **weak non-selective monoamine reuptake inhibitor with additional weak SERT-releasing activity**. Roberts et al. (2017 [Ref 2]) describe it as inhibiting "the re-uptake of serotonin and dopamine in a dose-dependent manner," consistent with McLaughlin's findings.

⚠️ **CRITICAL FLAG — Pharmacological Class Discrepancy:** The seed data classifies mexedrone as "Dopamine releasing agent, Norepinephrine releasing agent, Serotonin releasing agent." This is **incorrect** per McLaughlin et al. (2017 [Ref 1]). Mexedrone is explicitly devoid of releasing activity at DAT and NET. Only at SERT does it display weak releasing activity. The correct pharmacological classification should be: **Weak monoamine reuptake inhibitor (DAT, NET, SERT) / weak SERT-preferring releaser.** This misclassification has downstream safety implications. Flag for editorial correction.

### Receptor Binding

- **5-HT₂ receptors:** Roberts et al. (2017 [Ref 2]) report affinity for serotonin membrane receptors (5-HT₂). Jeon et al. (2024 [Ref 3]) confirmed via pharmacological antagonism studies that locomotor effects in mice are mediated at least in part by the **5-HT₂A receptor**: pre-treatment with the selective 5-HT₂A antagonist M100907 (0.5 or 1.0 mg/kg) reversed mexedrone-induced hyperlocomotion.
- **D2 receptors:** Roberts et al. (2017 [Ref 2]) report affinity for the D2 dopamine receptor.
- **DAT binding mode:** Molecular docking studies by Senior et al. (2020 [Ref 14]) showed mexedrone preferentially binds the **S1/central site** of DAT, NET, and SERT — the same binding site as classical monoamine reuptake inhibitors. Key intermolecular interactions involve tyrosine and aspartic acid residues at DAT. Notably, the experimental potency trends across transporters were only reproduced computationally in the case of mexedrone (not MDAI or phenibut), validating the docking model.

### Comparison to Mephedrone

The alpha-methoxy substitution markedly reduces mexedrone's activity compared to its parent compound mephedrone. Baumann et al. (2018 [Ref 17/24]) and Rickli et al. (2015 [Ref 23]) document that mephedrone (the parent) is a potent multi-transporter substrate-type releaser (i.e., a true releasing agent at DAT, NET, and SERT), which explains mephedrone's stronger entactogenic and euphoriant profile. Mexedrone's alpha-methoxy group abolishes releasing activity at DAT and NET and weakens SERT releasing activity compared to mephedrone, resulting in a notably weaker and different pharmacological profile (Nadal-Gratacós et al. 2024 [Ref 15]; McLaughlin et al. 2017 [Ref 1]).

The positional isomer N-methoxymephedrone differs significantly: it is a fully efficacious substrate-type releasing agent across all three transporters with EC₅₀ values in the low micromolar range (McLaughlin et al. 2017 [Ref 1]).

### In Vivo Pharmacology (Preclinical)

Jeon et al. (2024 [Ref 3]) characterized mexedrone's abuse potential using multiple behavioral paradigms in mice and rats:

- **Conditioned Place Preference (CPP):** Mexedrone (10–50 mg/kg, i.p.) produced dose-dependent significant CPP in male mice.
- **Self-Administration:** Mexedrone (0.1–0.5 mg/kg/infusion, i.v.) maintained dose-dependent self-administration behavior in male rats.
- **Drug Discrimination:** Mexedrone (5.6–32 mg/kg) fully substituted for the discriminative stimulus effects of cocaine in rats trained to discriminate cocaine from saline.
- **Locomotor Activity:** Mexedrone increased locomotor activity in mice; reversed by 5-HT₂A antagonist M100907, implicating serotonergic mechanisms.
- **Neurochemical:** Acute mexedrone (50 mg/kg) increased c-Fos expression in the dorsal striatum, decreased SERT protein levels in the dorsal striatal synaptosome fraction, and elevated extracellular 5-HT. This indicates SERT downregulation with repeated stimulation.

All preclinical data are from rodent models (mice and rats). No controlled human pharmacological trials of mexedrone have been published.

### Metabolism and CYP Involvement

Camuto et al. (2022 [Ref 4]) conducted a comprehensive in vitro Phase I metabolic profiling of mexedrone using human liver microsomes (HLM) and single recombinant CYP450 isoforms:

- **Primary metabolic reactions:** Hydroxylation, N-dealkylation, O-dealkylation
- **Principal CYP enzymes:**
  - **CYP2C19** — primary enzyme responsible for both hydroxylation and dealkylation reactions
  - **CYP2D6** — involved in hydroxylation only
  - **CYP1A2** — involved in hydroxylation only
- **Recommended markers of intake:** Unchanged mexedrone (significant fraction detected unchanged) and hydroxylated metabolites
- **Study limitation:** In vitro HLM study only; no published in vivo human pharmacokinetic data

For comparison, its structural analog mephedrone is metabolized primarily by CYP2D6 in humans (Olesti et al. 2019 [Ref 11]). The shift to CYP2C19 as primary enzyme for mexedrone reflects the steric influence of the alpha-methoxy group. CYP2C19 is a highly polymorphic enzyme; poor metabolizers (estimated 2–3% of Europeans) may accumulate higher mexedrone plasma concentrations, potentially increasing adverse effects.

### Mutagenicity and Cytotoxicity

Lenzi et al. (2021 [Ref 5]) evaluated genotoxicity using the micronucleus (MN) assay in TK6 lymphoblastoid cells:
- Mexedrone at 35–100 μM demonstrated **direct mutagenic potential** in TK6 cells without metabolic activation
- No statistically significant increase in reactive oxygen species (ROS) at tested concentrations — the mechanism of genotoxicity is not ROS-mediated
- Alpha-PVP and alpha-PHP, by contrast, were not directly mutagenic (only metabolites showed mutagenicity with metabolic activation)
- The concentration range (35–100 μM) is high relative to expected therapeutic/recreational plasma levels, so clinical relevance of in vitro mutagenicity requires contextual interpretation (flagged for editorial review)

---

## History

### Discovery and Market Appearance

Mexedrone was first identified on the illicit research chemical market in **August 2015**, when it was advertised and sold by UK internet retailers as a legal, non-controlled alternative to mephedrone (McLaughlin et al. 2017 [Ref 1]). Its design exploited the legal gap in UK drug law at the time: by introducing the alpha-methoxy group to mephedrone's structure, the compound avoided the existing cathinone-specific scheduling controls under the UK Misuse of Drugs Act 1971 while retaining some psychoactive activity.

The compound was of "particular interest to countries who operate generic drugs legislation" (McLaughlin et al. 2017 [Ref 1]) — a reference to nations employing broad cathinone class scheduling or structural similarity bans.

### First Scientific Characterization

Two simultaneous reports in 2016 were among the first to characterize mexedrone scientifically:
1. **Qian et al. (2016/2017 [Ref 6])** — analytical characterization via LC-QTOF-MS, GC-MS, and NMR spectroscopy; described as "the first report" on the compound's chemical data
2. **McLaughlin et al. (2016/2017 [Ref 1])** — full synthesis, spectroscopic characterization, X-ray crystal structure, and monoamine transporter pharmacology; the definitive pharmacological characterization

### First Clinical Cases

Roberts et al. (2017 [Ref 2]) published the first analytically confirmed clinical case series — 11 patients identified among 305 screened cases in Birmingham, UK. This represented the first documentation of real-world human exposure with toxicological confirmation.

### Regulatory History

- **Sweden:** Controlled substance since January 26, 2016 [Ref 28]
- **Japan:** Controlled since August 24, 2016 [Ref 28]
- **United Kingdom:** Banned under the Psychoactive Substances Act 2016, which came into force May 26, 2016. This blanket ban on all psychoactive substances not specifically exempted effectively prohibited mexedrone regardless of its specific structural characteristics.
- **United States:** No specific DEA scheduling identified. Mexedrone may fall under the Federal Analogue Act (Controlled Substances Analogue Enforcement Act of 1986) as a structural analog of the Schedule I substance mephedrone, but no explicit legal determination has been identified in the literature searched.
- **EU (other):** No specific EMCDDA formal risk assessment for mexedrone identified. Individual EU member state scheduling may vary. The 2016 EMCDDA annual report covered NPS notifications but no formal mexedrone risk assessment was retrieved.

---

## Subjective Effects

### Analytically Confirmed Clinical Data (Roberts et al. 2017 [Ref 2])

The only published clinically confirmed data on mexedrone's subjective and physiological effects comes from 11 cases identified at City Hospital, Birmingham. Key clinical features:

- **Agitation:** Most common presenting feature, observed in 10 of 11 patients. In some cases the agitation was "marked to the extent of aggression," with 6 patients requiring sedation and/or physical restraint
- **Tachycardia (>100 bpm):** 7 of 11 patients
- **Delusions and hallucinations with paranoia:** 3 patients, with a "prominent supernatural/demonic theme." None of these individuals had a prior psychiatric history of psychosis
- **Clinical course:** Median length of stay was 20 hours (range 2–77 hours; IQR 4–33). Patients typically recovered fully within 24 hours unless requiring sedation
- **Attribution caution:** Mexedrone alone was likely responsible for the clinical features in only 2 of the 11 cases. In 7 cases, other stimulants detected were more likely responsible. In 2 other cases, mexedrone was found in high concentration alongside substantial amounts of other stimulants, with contributing effects

### Duration and Dose Correlation

No published controlled human pharmacokinetic or dose-escalation studies exist for mexedrone. The seed data dose table (Threshold 50 mg / Light 100–150 mg / Common 150–250 mg / Strong 250–350 mg, oral; total duration 4–6 hours) is derived from community reports. This is consistent with PsychonautWiki documentation and is biologically plausible given mexedrone's structural similarity to mephedrone, for which controlled trials demonstrate 50–200 mg oral doses with duration consistent with a 4–6 hour window (Olesti et al. 2019 [Ref 11]). No published source contradicts these community-derived dose figures.

### Effect Profile from Cathinone Class Literature

From user-perspective qualitative research on cathinone class (Assi et al. 2017 [Ref 16]):
- Desired effects reported by cathinone users: increased energy, euphoria, empathogenic effects
- Adverse effects: anxiety, hallucinations, nervousness, paranoia (CNS); angina, myocardial infarction, tachycardia (cardiovascular); renal difficulty

These class-level effects are consistent with mexedrone's pharmacological profile and the Roberts 2017 clinical cases. Mexedrone's weaker pharmacological profile relative to mephedrone (due to alpha-methoxy substitution) suggests less potent euphoriant and entactogenic effects than mephedrone, though direct comparative human data do not exist.

---

## Safety & Toxicity

### Acute Toxicity (Clinical Cases)

Roberts et al. (2017 [Ref 2]):
- Dominant clinical features: agitation, tachycardia, and (in a minority) psychotic symptoms
- All 11 cases recovered; no deaths attributable to mexedrone in this series
- Polydrug use was highly prevalent (mexedrone rarely used alone)

### Fatality Data

Pieprzyca et al. (2023 [Ref 7]):
- "Pioneering data on concentrations and effects" of mexedrone detected in mixed-substance poisoning cases
- Publication reports blood concentration data in fatality context, though mexedrone was one of multiple substances
- All fatal cases in this series involved multiple organ failure
- Polydrug use (multiple cathinones and/or other psychoactive substances simultaneously) was identified as a significant contributor to increased SC toxicity
- Mexedrone-specific lethal blood concentrations not isolable from polydrug context in this dataset

### Mutagenicity

Mexedrone demonstrated direct mutagenic potential in TK6 lymphoblastoid cells at 35–100 μM (Lenzi et al. 2021 [Ref 5]). The mechanism does not involve ROS. Clinical relevance at recreational concentrations is unknown and requires in vivo corroboration.

### Cardiovascular Risk

Based on mechanism (monoamine reuptake inhibition) and clinical data, mexedrone produces sympathomimetic effects including tachycardia. More severe cardiovascular toxicity (hypertension, arrhythmia) is characteristic of the broader cathinone class (Paillet-Loilier et al. 2014 [Ref 18]; Baumann et al. 2014).

### Psychotomimetic Risk

Roberts et al. (2017 [Ref 2]) documented psychotic symptoms (hallucinations, delusions with paranoid content) in 3 of 11 cases, in patients without prior psychiatric history, suggesting mexedrone (or polydrug combinations) can precipitate acute psychosis. This is consistent with cathinone class effects more broadly (Weinstein et al. 2017).

### Unknown Toxic Dose

⚠️ **FLAG:** No published human LD50 or definitive toxic threshold for mexedrone. The seed data states "exact toxic dosage is unknown," which is confirmed. No preclinical LD50 has been published for mexedrone specifically.

---

## Harm Reduction

### Identification

Mexedrone can be identified using the following reagent tests (Reagent Tests UK [Ref 20]):
- **Marquis reagent:** No color change; fizzing observed
- **Froehde reagent:** No color change
- **Liebermann reagent:** Orange/yellow color change

The absence of color change with both Marquis and Froehde, combined with a positive Liebermann result, distinguishes mexedrone from many other cathinones and amphetamines. Testing with multiple reagents is recommended.

### No Specific Antidote

No antidote exists for mexedrone overdose. Management must be extrapolated from cocaine and amphetamine toxicity protocols (Paillet-Loilier et al. 2014 [Ref 18]). Treatment is symptomatic and supportive: benzodiazepines for agitation and seizures; cooling for hyperthermia; cardiac monitoring.

### Dose Caution

Community-derived dose guidance (Threshold 50 mg oral; Heavy 350+ mg) has not been validated in controlled trials. Individual variability in CYP2C19 metabolism is expected to affect plasma concentrations significantly. Poor metabolizers at CYP2C19 (approximately 2–5% of individuals depending on ancestry) may be at higher risk of adverse effects.

### Contraindications

⚠️ The following interactions are either documented or strongly predicted to be dangerous:
1. **Tramadol:** Listed as lethal in the seed data. Mechanism: Tramadol is a SERT inhibitor (Baldo 2018 [Ref 22]) with additional serotonergic and GABAergic activities. Combined with mexedrone's SERT inhibition and weak SERT-releasing activity, the combination creates additive serotonergic overload with risk of serotonin syndrome, hyperthermia, and death.
2. **MDMA:** Listed as dangerous in the seed data. Mechanism: MDMA is a potent multi-transporter releasing agent (especially SERT) producing massive serotonin release. Combined with mexedrone's SERT-inhibiting and weak releasing properties, combined serotonin toxicity risk is very high. MDMA also produces hyperthermia which the cathinone component may potentiate.
3. **MAO inhibitors:** Not listed in seed data but strongly contraindicated on pharmacological grounds. MAOIs prevent monoamine breakdown; combined with mexedrone's SERT inhibition/releasing activity, this could produce hypertensive crisis and severe serotonin syndrome.
4. **Alcohol:** Listed as "unknown" interaction in seed data. Per cathinone class literature (Contrucci et al. 2020 [Ref 21]), stimulant-alcohol combinations mask signs of intoxication, increase cardiac strain, and promote dehydration. Neither confirmed nor refuted as specifically dangerous.

### Polydrug Use Hazard

Roberts et al. (2017 [Ref 2]) and Pieprzyca et al. (2023 [Ref 7]) both document that mexedrone is typically used alongside other psychoactive substances. Clinical outcomes appear substantially worse in polydrug contexts. Users should be warned that mexedrone is rarely the sole substance in clinical presentations.

---

## Tolerance & Dependence

### Abuse Potential (Preclinical)

Jeon et al. (2024 [Ref 3]) demonstrated in multiple preclinical paradigms that mexedrone has significant abuse potential:
- Conditioned place preference: positive in mice (10–50 mg/kg)
- Self-administration: positive in rats (0.1–0.5 mg/kg/infusion)
- Cocaine-like discriminative stimulus: full substitution in rats

These findings indicate mexedrone has meaningful reinforcing properties. The serotonergic mechanism (5-HT₂A involvement in locomotor effects, SERT downregulation after acute dose) suggests a complex neuroadaptive profile.

### Tolerance and Dependence Data

The seed data states:
- Tolerance buildup: "develops with prolonged and repeated use"
- Tolerance half-life: 5 days
- Full reset: 1.5 weeks
- Cross-tolerances: dopamine, stimulant

No published human data or mexedrone-specific preclinical tolerance studies were identified to confirm or refute these values. These appear to be inferred from the cathinone class (likely mephedrone literature) rather than substance-specific research. They are biologically plausible given mexedrone's monoaminergic mechanism and the known tolerance patterns of cathinone stimulants, but should be flagged as class inference.

**Dependence:** The seed data classifies mexedrone as having "moderate" physical and psychological dependence potential with "moderately addictive" formation. This is consistent with preclinical evidence from Jeon et al. (2024 [Ref 3]) and with the cathinone class generally. No published human dependence case series for mexedrone specifically was identified.

---

## Interactions

### Documented or Strongly Predicted Dangerous Interactions

| Interaction | Severity (Seed) | Mechanism | Evidence Source |
|---|---|---|---|
| MDMA | Dangerous | Additive serotonergic toxicity; 5-HT excess → syndrome, hyperthermia | Class pharmacology [Refs 17, 22] |
| Tramadol | Lethal | Tramadol inhibits SERT + mexedrone SERT inhibition/releasing = severe serotonin syndrome | Baldo 2018 [Ref 22]; Lagard 2022 [Ref 25] |
| Alcohol | Unknown | No specific mexedrone-alcohol interaction data | Not found in literature |
| MAOIs | Not listed | Prevent monoamine breakdown; hypertensive crisis + serotonin syndrome risk | Class inference [Ref 18, 26] |
| SSRIs/SNRIs | Not listed | Additive serotonergic activity; serotonin syndrome risk | Contrucci et al. 2020 [Ref 21]; Baldo 2018 [Ref 22] |

### Tramadol Interaction — Mechanism Detail

Tramadol inhibits serotonin reuptake via human SERT (confirmed in HEK293 cell studies; Baldo 2018 [Ref 22]). When combined with mexedrone — itself a SERT inhibitor with weak SERT-releasing properties — the combined serotonergic burden creates risk of serotonin syndrome characterized by hyperthermia, autonomic instability, neuromuscular hyperactivity, and potentially death. The seed data classification of this interaction as "lethal" is pharmacologically consistent with published mechanisms, though no published case report specifically documenting a mexedrone–tramadol fatality was identified. This should be flagged as supported by mechanism rather than a confirmed published fatality.

### CYP Interaction Potential

Mexedrone is primarily metabolized by CYP2C19 (Camuto et al. 2022 [Ref 4]). Drugs that inhibit CYP2C19 (e.g., omeprazole, fluoxetine, fluvoxamine) may increase mexedrone plasma concentrations significantly. Inducers of CYP2C19 (e.g., rifampicin, carbamazepine) may reduce efficacy. CYP2C19 drug interactions have not been studied for mexedrone specifically but are expected from the metabolic data.

---

## Legal Status

| Jurisdiction | Status | Date | Notes |
|---|---|---|---|
| United Kingdom | **Illegal** | May 26, 2016 | Psychoactive Substances Act 2016; blanket ban on all psychoactive substances not specifically exempted |
| Sweden | **Controlled** | January 26, 2016 | [Ref 28] |
| Japan | **Controlled** | August 24, 2016 | [Ref 28] |
| United States | **Unconfirmed** | — | Not explicitly DEA-scheduled; Federal Analogue Act may apply as structural analog of Schedule I mephedrone, but no confirmed legal determination found |
| European Union | **Varies by member state** | — | No formal EMCDDA risk assessment for mexedrone found; national scheduling varies; not EU-wide scheduled |
| Australia | **Unknown** | — | No published data found on Australian scheduling status |
| Canada | **Unknown** | — | No published data found |

**Prior to May 2016:** Mexedrone was legal in the UK and explicitly marketed online as a non-controlled research chemical, exploiting the absence of specific structural scheduling for alpha-methoxy cathinones.

---

## Clinical Trials

No clinical trials involving mexedrone are registered in ClinicalTrials.gov (search performed May 2026). No published controlled human trials exist. This is consistent with mexedrone's status as a recently emerged designer substance with no therapeutic applications.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### ⚠️ Safety-Critical: Pharmacological Class Misclassification
**FLAG — Requires editorial correction before publication.**

The seed data classifies mexedrone as a "Dopamine releasing agent, Norepinephrine releasing agent, Serotonin releasing agent." This is directly contradicted by the primary pharmacological characterization (McLaughlin et al. 2017 [Ref 1]):

> "Mexedrone was a weak non-selective uptake blocker with IC₅₀ values in the low μM range. It was also **devoid of releasing activity at DAT and NET** but displayed weak releasing activity at SERT (EC₅₀ = 2.5 μM)."

Correct classification: **Weak non-selective monoamine reuptake inhibitor (DAT, NET, SERT), with weak SERT-releasing activity.** This is a reuptake inhibitor, not a releasing agent, for dopamine and norepinephrine. This distinction matters for understanding the drug's clinical effects and interaction profile.

### ⚠️ Safety-Critical: Lethal Dose Unknown
No published LD50 or confirmed toxic threshold for mexedrone in humans or confirmed laboratory animals exists. All fatality data involves polydrug use (Pieprzyca et al. 2023 [Ref 7]). The stated "exact toxic dosage is unknown" in the seed data is confirmed accurate.

### ⚠️ Safety-Critical: Tramadol Interaction — Mechanism Not Fatality-Confirmed
The seed data labels tramadol as a "lethal" interaction. The pharmacological mechanism is scientifically supported (additive SERT inhibition + serotonin toxicity risk; Baldo 2018 [Ref 22]). However, no published case report specifically documenting a mexedrone–tramadol fatality was identified. The severity label is plausible but rests on mechanistic inference rather than a confirmed published fatality specific to this drug pair. Generation agent should label interaction severity accurately.

### Missing Chemical Data
- **SMILES string** not returned by PubChem API call; can be retrieved directly from the PubChem CID 129318262 page. The SMILES is: `COC[C@@H](NC)C(=O)c1ccc(C)cc1` (racemate: `COCC(NC)C(=O)c1ccc(C)cc1`) — note: this is inferential based on structure; generation agent should verify from PubChem directly.
- **Melting point, solubility, partition coefficient (logP):** Not retrieved from PubMed or PubChem API. McLaughlin et al. (2017 [Ref 1]) obtained the crystal structure (which may include melting point data in the full text, not accessible via API).

### Missing Pharmacokinetic Data
No published human pharmacokinetic data for mexedrone: Tmax, Cmax, bioavailability, plasma half-life, volume of distribution, urinary excretion are all unknown. The tolerance half-life (5 days) and reset (1.5 weeks) in the seed data are class inferences, not mexedrone-specific measurements. Flagged as requiring editorial note in the article.

### Quantitative IC₅₀ Values
McLaughlin et al. (2017 [Ref 1]) report IC₅₀ values only as "low μM range" in the abstract. Specific numerical IC₅₀ values for DAT, NET, and SERT (and comparison to mephedrone) require full-text access, not available via API. Generation agent should note values as "low micromolar" rather than providing specific numbers without full-text verification.

### Stereochemistry
Mexedrone possesses a chiral center at C-2. No published data on individual enantiomer pharmacology was found. Mephedrone studies have found enantiomers differ in transporter affinity (Michal et al. 2025 review). Whether this applies to mexedrone is unknown.

### US Legal Status
No explicit DEA scheduling determination found. The Federal Analogue Act may apply, but no case law, DEA emergency scheduling, or published legal analysis for mexedrone was identified.

### Australian and Canadian Legal Status
Not found in any retrieved literature. Should be verified via government scheduling databases before publication.

### Mutagenicity Clinical Relevance
The mutagenic potential found by Lenzi et al. (2021 [Ref 5]) was at 35–100 μM in cell culture. Whether recreational-use plasma concentrations reach this range is unknown without human PK data. Article should note this limitation.

### No Controlled Human Trials
All human-relevant data derives from a single case series (Roberts et al. 2017, n=11) in which mexedrone was rarely the sole substance. All other pharmacology is from in vitro or animal studies. Generation agent should clearly label evidence levels throughout.